Company intelligence / Profile preview

1606 Corp

Seattle, Washington, United States

Ownership: Private
Development stage: Other

Overview

1606 Corp, via its strategic partnership and investment in Adnexus Biotech, is leveraging cutting-edge AI to discover fully human monoclonal antibodies for the treatment of infectious diseases, such as HIV and SARS-CoV-2. The proprietary Sutra AI platform integrates immune-B cell screening and has produced antibodies validated on targets from 19 viruses. There are no clinical-stage results disclosed as of December 2024.

Therapeutic areas: Infectious DiseasesNeurology
Modalities: Monoclonal antibodyAI-enabled therapeutics
Industry: Biotech

Partnerships

Adnexus Biotech

Beyond the preview

Go deeper on 1606 Corp.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1606 Corp.

Explore the full profile